The Claim
In adults with obesity and type 2 diabetes, administration of bimagrumab reduces visceral adipose tissue by approximately 36.1% and hepatic fat fraction by 23.6% within 24 weeks, independent of changes in caloric intake, indicating a direct effect on ectopic fat deposition.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with obesity and type 2 diabetes, bimagrumab reduces visceral fat by 36.1% and liver fat by 23.6% within 24 weeks, regardless of changes in calorie intake.
See the scientific wording
In adults with obesity and type 2 diabetes, bimagrumab reduces visceral adipose tissue by approximately 36.1% and hepatic fat fraction by 23.6% within 24 weeks, independent of changes in caloric intake, indicating a direct effect on ectopic fat deposition.
Bimagrumab blocks specific receptors on muscle and fat cells, which stops signals that normally limit muscle growth and promote fat storage. This causes muscle to grow larger and fat cells to store less fat, especially in the belly and liver, without needing to eat less.
What the research says
1 studyThe study found that a drug called bimagrumab shrunk dangerous belly and liver fat by over 20% in people with obesity and diabetes—even when they didn’t eat less—proving it works directly on fat inside organs.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.